Overview

Safety and Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) Plus Valsartan in Patients With Kidney Transplants (MYTHOS

Status:
Completed

Trial end date:
2005-06-01

Target enrollment:

Participant gender:

Summary

The primary aim of this study is to evaluate the safety and efficacy of EC-MPS plus valsartan as part of an intensified multifactorial intervention on the reduction of the 12-month rate of transplant nephropathy compared with EC-MPS plus standard practice of care in recipients of a first cadaver donor kidney transplant given CsA-ME, basiliximab, and short-term steroids.

Phase:

Phase 3

Details

Lead Sponsor:

Novartis

Treatments:

Mycophenolate mofetil
Mycophenolic Acid
Valsartan